IL-17 cytokines preferentially act on naïve CD4+ T cells with the IL-17AF heterodimer inducing the greatest functional changes

Michael P. Crawford; Nicholas Borcherding; Nitin J. Karandikar

doi:10.1371/journal.pone.0285166

Peer Review History

Original SubmissionFebruary 21, 2023
12 Apr 2023 Decision Letter - Pierre Bobé, Editor PONE-D-23-05159IL-17 cytokines preferentially act on naïve CD4+ T cells with the IL-17AF heterodimer inducing the greatest functional changesPLOS ONE Dear Dr. Karandikar, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by May 19 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript: A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Prof. Pierre Bobé Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes ******** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes ****** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes ****** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes ****** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: The authors highlighted differential effect of IL-17 stimulation on naïve or memory CD4 T cells, as well as IL-17AF efficiency in promoting suppression-resistance of naïve CD4 T cells. The experiments have been conducted in a very satisfying way and the data therefore strongly support the authors’ conclusions. Some minor modifications still must be made: Nomenclature should be harmonized throughout the manuscript, e.g. IL17 receptor (Abstract line 37), anti-IL4 (Materials line 104), all CD4+ should be replaced by CD4+. Similarly, some minor typo should be corrected, e.g. AlexaFlour (Materials, line 130) Reviewer suggestions: In figure 2D, it could be informative to add on the graph the statistical comparison of the proliferation percentage between Memory and Naïve for each tested ratio. The same apply for Figure 3D, in which statistical comparison between “Same Well” and “Individually” could be informative. For those two figures, highlighting the lack of statistical difference between the condition could reinforce the authors’ findings. ****** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No ******** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. https://doi.org/10.1371/journal.pone.0285166.r001
Revision 1
14 Apr 2023 Author Response Re: Amended Manuscript PONE-D-23-05159 We would like to thank the editors and the reviewers for the constructive review of our manuscript and appreciate the opportunity to address your comments in our amended re-submission. Here are point-by-point responses to the comments: 1. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data. We thank the editors for this comment/reminder. At one spot in the manuscript, we have removed the phrase completely as the data are not a core part of this study. At the other two places, we have replaced the “data not shown” phrase with the GEO public database information as these data are already shared there. 2. Reviewer #1: The authors highlighted differential effect of IL-17 stimulation on naïve or memory CD4 T cells, as well as IL-17AF efficiency in promoting suppression-resistance of naïve CD4 T cells. The experiments have been conducted in a very satisfying way and the data therefore strongly support the authors’ conclusions. Some minor modifications still must be made: Nomenclature should be harmonized throughout the manuscript, e.g. IL17 receptor (Abstract line 37), anti-IL4 (Materials line 104), all CD4+ should be replaced by CD4+. Similarly, some minor typo should be corrected, e.g. AlexaFlour (Materials, line 130) We thank the reviewer for these catches. We have now consistently added the hyphen when referring to the cytokine protein or receptor. Similarly, we have now superscripted the “+” and “-“ (positive and negative) references for CD4 as well as other markers (CD25, CD45RO, etc.). We have corrected the typo in line 130 as well. 3. Reviewer suggestions: In figure 2D, it could be informative to add on the graph the statistical comparison of the proliferation percentage between Memory and Naïve for each tested ratio. The same apply for Figure 3D, in which statistical comparison between “Same Well” and “Individually” could be informative. For those two figures, highlighting the lack of statistical difference between the condition could reinforce the authors’ findings. We thank the reviewers for these suggestions. We have conducted these statistical comparisons. To avoid clutter in the figures, we have only shown the statistically significant differences with asterisks. However, as suggested by the reviewers, we have now added a description about the non-significant comparisons within the text of the manuscript to highlight them and to reinforce our findings. We hope that the modifications in the manuscript have addressed the reviewers’ and editors’ feedback and look forward to its publication in the PLOS ONE. Attachments Attachment Submitted filename: RESPONSE-TO-REVIEWERS-v041323.docx https://doi.org/10.1371/journal.pone.0285166.r002
18 Apr 2023 Decision Letter - Pierre Bobé, Editor IL-17 cytokines preferentially act on naïve CD4+ T cells with the IL-17AF heterodimer inducing the greatest functional changes PONE-D-23-05159R1 Dear Dr. Karandikar, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Prof. Pierre Bobé Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: https://doi.org/10.1371/journal.pone.0285166.r003
Formally Accepted
20 Apr 2023 Acceptance Letter - Pierre Bobé, Editor PONE-D-23-05159R1 IL-17 cytokines preferentially act on naïve CD4⁺ T cells with the IL-17AF heterodimer inducing the greatest functional changes Dear Dr. Karandikar: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Prof Pierre Bobé Academic Editor PLOS ONE https://doi.org/10.1371/journal.pone.0285166.r004

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .